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Received 9 April 2014; Accepted 9 May 2014; Published 21 May 2014
Academic Editor: Vinod K. Mishra
Copyright © 2014 Fernanda Genre et al.This is an open access article distributed under theCreativeCommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. TRAIL is a potential biomarker of cardiovascular (CV) disease. Ankylosing spondylitis (AS) is a chronic inflammatory
disease associated with metabolic syndrome (MeS) and accelerated atherosclerosis. We assessed whether disease activity, systemic
inflammation, and MeS features were associated with circulating TRAIL levels in AS patients undergoing TNF-𝛼 antagonist
infliximab therapy and if infliximab infusionmodified TRAIL levels.Methods. Wemeasured TRAIL serum levels in 30 nondiabetic
AS patients without CV disease undergoing anti-TNF-𝛼 therapy, immediately before and after an infliximab infusion, and in
48 matched controls. Correlations of TRAIL levels with disease activity, systemic inflammation and MeS features, adipokines,
and biomarkers of endothelial activation were evaluated. Changes in TRAIL levels following anti-TNF-𝛼 infusion were analyzed.
Results. TRAIL levels were higher in AS patients than controls. TRAIL levels displayed an inverse correlation with total and LDL
cholesterol.We observed an inverse correlation withQUICKI and amarginal association withHOMA-IR.We also found an inverse
correlation with resistin and a marginal association with apelin and OPN. Anti-TNF-𝛼 infusion did not change TRAIL levels after
120󸀠. Conclusion. Elevated TRAIL levels in AS patients may be the result of a compensatory mechanism to reduce CV risk in these
patients.
1. Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory dis-
ease associated with high incidence of cardiovascular (CV)
mortality due to accelerated atherosclerosis [1]. In addition,
AS patients often displaymetabolic syndrome (MeS) features,
which include obesity, dyslipidemia, hypertension, alter-
ations in glucose metabolism, including insulin resistance
(IR), and also a dysregulation of adipokines [2]. Anti-TNF-𝛼
therapy has proven to be effective for the treatment of AS [3].
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Interestingly, a single infusion of anti-TNF-𝛼 monoclonal
antibody infliximab improved insulin sensitivity in nondia-
betic AS patients [4]. Additionally, beneficial effects of anti-
TNF-𝛼 on adipokines, biomarkers of atherosclerosis, and
MeS-related biomarkers were also found in AS [5–12]. Since
TNF-𝛼 blockade may account for biological changes that
may slow the progression of atherosclerosis in AS patients
[13], the analysis of the potential influence of treatment with
anti-TNF-𝛼 drugs on disease activity, systemic inflammation,
MeS, and new potential CV risk biomarkers might help
us to understand the effect of these biologic agents on the
mechanism associated with atherosclerosis in AS patients.
TNF-related apoptosis-inducing ligand (TRAIL) belongs
to the TNF superfamily and was proposed as a potential
biomarker of CV disease [14]. This protein can be expressed
on the cell surface, as a transmembrane protein, or secreted
as a soluble protein [15]. Apart from being involved in the
apoptotic process, TRAIL also exerts anti-inflammatory and
antiatherosclerotic functions [16–18].
Taking all these considerations into account, in the
present study, we aimed to study if TRAIL serum levels
were altered in AS patients undergoing infliximab therapy
when compared to controls.We also aimed to assess potential
associations between disease activity, systemic inflammation,
adipokines, biomarkers of endothelial activation, and MeS
features with circulating TRAIL levels in these patients.
Finally, we also aimed to determine whether an anti-TNF-
𝛼monoclonal antibody infliximab infusion modified TRAIL
levels.
2. Patients and Methods
2.1. Patients. We assessed a series of 30 patients with AS
attending hospital outpatient clinics seen over 14 months
(January 2009 to March 2010), who fulfilled the modified
New York diagnostic criteria for AS [19]. They were treated
by the same group of rheumatologists and were recruited
from the Hospital Lucus Augusti (Xeral-Calde), Lugo, Spain.
For the comparative analysis with AS patients, we used 48
controls matched by age, sex, ethnicity, and traditional CV
risk factors, who did not have history of CV events.
For ethical reasons, patients included in the present study
were not randomized to a placebo group.The same procedure
has been found acceptable and followed in studies on the
short-term effect of infliximab therapy on adipokines and
biomarkers of endothelial cell activation in patients with
rheumatoid arthritis (RA) [20–22].
Patients on treatment with infliximab seen during the
period of recruitment with diabetes mellitus or with plasma
glucose levels greater than 110mg/dL were excluded. None
of the patients included in the study had hyperthyroidism or
renal insufficiency. Also, patients seen during the recruitment
period who had experienced CV events, including ischemic
heart disease, heart failure, cerebrovascular accidents, or
peripheral arterial disease, were excluded. Patients were
diagnosed as having hypertension if blood pressure was
≥140/90mmHg or they were taking antihypertensive agents.
Patients were considered to have dyslipidemia if they had
hypercholesterolemia and/or hypertriglyceridemia (defined
as diagnosis of hypercholesterolemia or hypertriglyceridemia
by the patients’ family physicians, or total cholesterol and/or
triglyceride levels in fasting plasma were >220mg/dL and
>150mg/dL, resp.). Obesity was defined if body mass index
(BMI) (calculated as weight in kilograms divided by height
in squared meters) was greater than 30.
In all cases, treatment with the anti-TNF-𝛼 monoclonal
antibody infliximab was started because of active disease. All
patients included in the current study had begun treatment
with NSAIDs immediately after the disease diagnosis. All of
them were still being treated with these drugs at the time
of the study. At the time of this study, most patients were
on treatment with naproxen 500–1000mg/d. Although the
2010 updated recommendations facilitate initiation of TNF-𝛼
blockers in AS and only ask for 2 NSAIDs with a minimum
total treatment period of 4 weeks [23], for the initiation
of anti-TNF-𝛼 therapy in these series of patients recruited
between January 2009 andMarch 2010, they had to be treated
with at least 3NSAIDs prior to the onset of infliximab therapy.
A clinical index of disease activity (Bath Ankylosing
Spondylitis Disease Activity Index—BASDAI—range of 0 to
10) [24] was evaluated in all patients at the time of the study.
Clinical information on hip involvement, history of synovitis
in other peripheral joints and peripheral enthesitis, history
of anterior uveitis, presence of syndesmophytes, and HLA-
B27 status (typed by cell cytotoxicity) was assessed. More-
over, C-reactive protein (CRP), by a latex immunoturbidity
method, erythrocyte sedimentation rate (ESR) (Westergren),
serum glucose, total cholesterol, HDL and LDL cholesterol,
and triglycerides (fasting overnight determinations) were
assessed in all the patients at the time of the study.
The main demographic, clinical, and laboratory data of
this series of 30 AS patients at the time of the study are shown
inTable 1. Since at that time all patients were undergoing peri-
odical treatment with the anti-TNF-𝛼 monoclonal antibody
infliximab (median duration of periodical treatment with this
biologic agent: 23 months), the mean BASDAI ± standard
deviation (SD) was only 2.94 ± 2.11.
The local institutional committee approved anti-TNF-𝛼
therapy. Also, patients gave informed consent to participate
in this study. Neither this study nor the former studies on the
short-term effect of infliximab therapy on insulin resistance,
adipokines, and biomarkers of endothelial cell activation in
AS were supported by any pharmaceutical drug company.
2.2. Study Protocol. In all cases, the drugwas given to patients
as an intravenous infusion in a saline solution over 120
minutes. All measurements were made in the fasting state.
Blood samples were taken at 0800 hours for determination
of the erythrocyte sedimentation rate (ESR) (Westergren), C-
reactive protein (CRP) (latex immunoturbidimetry), lipids
(enzymatic colorimetry), plasma glucose, and serum insulin
(DPC, Dipesa, Los Angeles, CA, USA). As previously
described, insulin resistance was estimated by the homeosta-
sis model assessment of insulin resistance (HOMA-IR) using
the formula (insulin (𝜇U/mL) × glucose (mmol/l) ÷ 22.57)
[4]. A commercial ELISA kit was used to measure serum
TRAIL levels (R&D Systems, DTRL00); assay sensitivity =
7.87 pg/mL; intra- and interassay coefficients of variation
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Table 1: Demographic, clinical, and laboratory data of 30 patients
with ankylosing spondylitis.
Variable 𝑛 (%)
Mean age (years) ± SD
At the time of study 50.47 ± 14.85
At the time of onset of symptoms 28.23 ± 10.40
Delay to the diagnosis (years) ± SD 11.48 ± 9.01
Men/women 21 (70)/9 (30)
Mean disease duration (years) ± SD∗ 21.97 ± 13.16
History of classic cardiovascular risk factors
Hypertension (𝑛 = 30) 12 (40)
Dyslipidemia (𝑛 = 30) 11 (36.67)
Obesity (BMI > 30 kg/m2) (𝑛 = 30) 3 (10.00)
Current smokers (𝑛 = 30) 13 (43.33)
Mean blood pressure (mmHg) ± SD∗
Systolic 123.17 ± 18.17
Diastolic 75.67 ± 12.51
Mean body mass index (kg/m2) ± SD 26.70 ± 3.26
Mean BASDAI ± SD∗ 2.94 ± 2.11
Mean VAS ± SD∗ 31.13 ± 24.23
Hip involvement, 𝑛 (%) (𝑛 = 30) 6 (20)
Synovitis and/or enthesitis in other peripheral
joints, 𝑛 (%) (𝑛 = 27) 11 (36.67)
Anterior uveitis, 𝑛 (%) (𝑛 = 30) 6 (20.00)
Syndesmophytes, 𝑛 (%) (𝑛 = 30) 10 (33.33)
Mean CRP (mg/L) ± SD∗∗
At the time of disease diagnosis 24.01 ± 33.43
At the time of study 6.24 ± 8.65
Mean ESR (mm/1st hour) ± SD∗∗∗
At the time of disease diagnosis 30.10 ± 28.23
At the time of study 19.00 ± 15.18
Mean cholesterol or triglycerides (mg/dL) ± SD∗
Total cholesterol 199.10 ± 30.61
HDL cholesterol 53.17 ± 12.81
LDL cholesterol 126.77 ± 26.54
Triglycerides 93.97 ± 56.70
Mean fasting serum glucose (mg/dL) ± SD∗ 92.77 ± 8.63
HLA-B27 positive (𝑛 = 27) 20 (74.07)
∗At the time of the study. ∗∗Normal value <5mg/L. ∗∗∗Normal value
<20mm/1st hour.
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BMI: body
mass index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate;
HDL: high-density lipoprotein; HLA: human leukocyte antigen; LDL: low-
density lipoprotein; SD: standard deviation; VAS: visual analogue scale.
were <3.9% and <6%, respectively (Minneapolis, MN, USA)
according to the manufacturer’s instructions. Serum levels
of TRAIL were measured in samples obtained immedi-
ately prior to an infliximab infusion and 120 minutes later.
Total plasma adiponectin and osteoprotegerin levels, serum
resistin, leptin, visfatin, apelin, angiopoietin-2 (Angpt-2),
asymmetric dimethylarginine (ADMA), gelsolin, osteopon-
tin (OPN), and retinol-binding protein 4 (RBP-4) levels
obtained immediately before infliximab infusion were deter-
mined by ELISA as previously described [5–12].
2.3. Statistical Analyses. Variables were expressed as mean
± SD, median, interquartile range (IQR), or percentages.
Correlation between basal TRAIL at time 0 and selected
continuous variables was performed, adjusting for age at
the time of the study, sex, and classic CV risk factors via
estimation of the Pearson partial correlation coefficient (𝑟).
The associations between baseline characteristics and
serum TRAIL concentrations were assessed by Student’s
paired 𝑡-test. Differences in TRAIL levels between men and
women and patients with hypertension or without were
assessed by the Mann-Whitney 𝑈 test.
TRAIL serum levels before (at time 0) and after infusion
(at time 120 minutes) were compared using the paired
Student’s 𝑡-test.
Two-sided 𝑃 values ≤ 0.05 were considered to indicate
statistical significance. Analyses were performed using Stata
12/SE (StataCorp, College Station, TX).
3. Results
3.1. Differences in TRAIL Serum Levels between AS Patients
and Controls. TRAIL serum levels were higher in AS patients
(mean ± SD: 160.57 ± 47.48 pg/mL;median (IQ range): 160.72
(128.69–195.99)) than in healthy controls (mean ± SD: 117.96
± 48.20 pg/mL;median (IQ range): 107.49 (85.32–137.31)) (𝑃 <
0.0003) (Figure 1).
3.2. Relationship of TRAILConcentrationwithDiseaseActivity
and Clinical Features. Circulating TRAIL levels did not
correlate with disease duration, BASDAI, or VAS spinal pain
at the time of the study (Table 2). Likewise, no difference
in TRAIL concentration was observed when patients with
a history of anterior uveitis, presence of syndesmophytes,
hip involvement or synovitis in other peripheral joints, and
peripheral enthesitis were compared with the remaining
patients who did not exhibit these characteristics. It was also
the case when patients were compared according toHLA-B27
status (data not shown).
3.3. Relationship of Demographic Features, Inflammation,
Adiposity, and Adipokines with Circulating TRAIL Levels.
TRAIL serum levels did not show significant association with
age at the onset of symptoms, BMI, and CRP and ESR at
the time of the study and at the time of disease diagnosis
(Table 2). Interestingly, we observed an inverse correlation of
TRAIL with resistin (𝑟 = −0.427; 𝑃 = 0.05) and a marginal
association with apelin (𝑟 = 0.373; 𝑃 = 0.06). No association
with the rest of adipokines was observed (Table 2). When
AS patients were stratified according to sex, no significant
differences were found in TRAIL serum levels (data not
shown).
3.4. Relationship of TRAIL Levels with Metabolic Syndrome
FeaturesOtherThanAdiposity. TRAIL serum levels displayed
an inverse correlation with total cholesterol (𝑟 = −0.393;
𝑃 = 0.04) and LDL cholesterol (𝑟 = −0.452; 𝑃 = 0.02). In
addition, we observed a negative correlation of TRAIL with
insulin sensitivity index (QUICKI: 𝑟 = −0.440; 𝑃 = 0.02) and
a marginal association with IR (HOMA-IR: 𝑟 = 0.368; 𝑃 =
0.06) (Table 2). However, we did not observe any association





















Figure 1: Box plot showing differences between AS patients and
healthy controls matched by age, sex, and traditional CV risk factors
in TRAIL serum concentration.
between TRAIL serum levels and systolic or diastolic blood
pressure, HDL cholesterol, triglycerides, or serum glucose
levels (Table 2). Likewise, we did not find any correlation
between TRAIL and RBP-4 levels (Table 2). Besides, no
significant differences in TRAIL serum levels were seen when
patients were stratified according to the presence or absence
of arterial hypertension (not shown).
3.5. Relationship of TRAIL Serum Levels with Biomarkers of
Endothelial Cell Activation and Atherosclerosis. No correla-
tion of TRAIL levels with Angpt-2 or ADMA was disclosed.
However, we found amarginally negative correlation between
TRAIL and OPN levels (𝑟 = −0.372; 𝑃 = 0.06) (Table 2).
3.6. Changes in TRAIL Levels upon Infliximab Therapy.
TRAIL serum levels did not change following an infliximab
infusion. In this regard, the mean ± SD values of TRAIL
were 160.57 ± 47.48 pg/mL immediately prior to infliximab
infusion (time 0) and 157.06 ± 65.90 pg/mL at the end of the
infusion (time 120 minutes) (𝑃 = 0.772).
4. Discussion
TRAIL is a molecule that has been proposed to be involved
in the pathophysiology of several autoimmune diseases, not
only for its role in the apoptotic process, but also for its func-
tions as an antiatherogenic and anti-inflammatory molecule
[25]. Additionally, several pieces of evidence support the
potential use of TRAIL as a biomarker of CV disease [14].
Since the implication of TRAIL inAS has not been completely
elucidated, in this study we aimed to further clarify the role
of this potential biomarker in the pathogenesis and in the
mechanisms associated with MeS and CV disease in AS.
In our study, patients with AS displayed low disease
activity (mean BASDAI: 2.94) due to prolonged biologic
therapy (median duration: 23 months). Interestingly, TRAIL
levels were higher in AS patients than in controls. In keeping
with our results, increased levels of TRAIL were found in
rheumatoid arthritis patients undergoing disease-modifying
antirheumatic drug therapy for 1 year when compared to
Table 2: Partial correlation of serum TRAIL prior to infliximab
infusion (at time 0) with selected continuous variables adjusted for
age at the time of the study, sex, and classic cardiovascular risk
factors (dyslipidemia, smoking, obesity, and hypertension) in 30
patients with ankylosing spondylitis.
Variable TRAIL (time 0)
𝑟 𝑃
Age at the onset of symptoms −0.026 0.90
Disease duration∗ −0.011 0.96
BMI∗ 0.042 0.84
Systolic blood pressure∗ 0.039 0.85
Diastolic blood pressure∗ 0.087 0.66
BASDAI∗ 0.089 0.66
VAS spinal pain∗ 0.135 0.50
ESR∗ (natural-log-transformed) 0.018 0.93
CRP∗ (natural-log-transformed) −0.080 0.69
ESR∗∗ (natural-log-transformed) 0.045 0.83
CRP∗∗ (natural-log-transformed) 0.011 0.96
Total cholesterol∗ (natural-log-transformed) −0.393 0.04
HDL cholesterol∗ (natural-log-transformed) −0.111 0.58
LDL cholesterol∗ (natural-log-transformed) −0.452 0.02
Atherogenic index∗ (total cholesterol/HDL) −0.180 0.38
Triglycerides∗ (natural-log-transformed) 0.185 0.36
Serum glucose∗ (natural-log-transformed) −0.092 0.65
HOMA-IR at time 0∗ 0.368 0.06
QUICKI at time 0∗ −0.440 0.02
Resistin at time 0 −0.427 0.05
Adiponectin at time 0 −0.009 0.97
Leptin at time 0 0.069 0.74
Visfatin at time 0 0.048 0.81
Angpt-2 at time 0 −0.055 0.79
Apelin at time 0 0.373 0.06
ADMA at time 0 −0.058 0.78
Gelsolin at time 0 0.173 0.39
OPN at time 0 −0.372 0.06
RBP-4 at time 0 0.318 0.11
Osteoprotegerin at time 0 0.044 0.83
∗At the time of the study. ∗∗At the time of disease diagnosis.
ADMA: asymmetric dimethylarginine; Angpt-2: angiopoietin 2; BASDAI:
Bath Ankylosing Spondylitis Disease Activity Index; BMI: body mass index;
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HDL: high-
density lipoprotein; HOMA-IR: homeostasis model assessment of insulin
resistance; LDL: low-density lipoprotein; OPN: osteopontin; QUICKI: quan-
titative insulin sensitivity check index; RBP-4: retinol-binding protein 4;
VAS: visual analogue scale.
controls [26]. Likewise, lupus patients with inactive disease
showed higher TRAIL levels than those with active disease,
even higher than those found in controls [25]. Additionally,
a study performed on Chinese AS patients also disclosed
higher TRAIL levels when compared to healthy controls [27].
Next, we investigated the potential association of TRAIL
with metabolic indices, since AS patients often display MeS
features [2]. In this regard, we disclosed an inverse correlation
of TRAIL with insulin sensitivity index and a marginal asso-
ciation with IR (HOMA-IR). A similar association between
TRAIL andHOMA-IRwas observed in diabetic patients [28].
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It is well known that IR is associated with inflammation [29];
therefore, an increase in the levels of the anti-inflammatory
TRAIL molecule would act to compensate such an inflam-
matory burden.
Furthermore, we also disclosed an inverse correlation of
TRAIL with the proinflammatory adipokine resistin and a
marginally negative association with the proinflammatory
biomarker of endothelial activation OPN. In line with these
results, a marginally positive correlation between TRAIL and
apelin, an anti-inflammatory adipokine, was also observed.
These results further support the previously described anti-
inflammatory role of TRAIL [17].
Unlike patientswith diabetes or obese individuals [15, 28],
in our study that included nondiabetic and mostly nonobese
(27 of 30) AS patients, there was a negative correlation
between TRAIL levels and total/LDL cholesterol. Chronic
inflammation is associated with a paradoxical decrease of
lipid levels [30, 31]. Despite having low disease activity
probably due to long-term anti-TNF-𝛼 therapy, a chronic
inflammatory state is plausible to exist in our patients (CRP
24 at disease diagnosis and 6.24mg/L at the time of the study).
In this regard, it was reported that CRP values greater than
3mg/L were associated with high risk of future CV events
[32]. Therefore, also in this situation, elevated TRAIL levels
may act to compensate the chronic inflammatory state that is
present in these patients (reflected by the inverse correlation
between TRAIL and total/LDL cholesterol as well as by the
presence of CRP levels above the normal range).
Finally, although the aim of the study was to evaluate the
immediate direct effect of an infliximab infusion on TRAIL
levels, adipokines, biomarkers of endothelial activation, and
metabolic syndrome, it may constitute by itself a potential
limitation since it is possible that the influence of infliximab
on TRAIL levels may require several steps before directly
reducing TRAIL levels. Therefore, further studies aimed at
determining the effect of infliximab on TRAIL levels at
different times, especially at later times, are needed to fully
establish the effect of anti-TNF-𝛼 blockade on TRAIL and
other molecules implicated in the mechanisms leading to CV
disease in AS.
5. Conclusion
In conclusion, our results suggest that elevated TRAIL lev-
els in AS patients may be the result of a compensatory
mechanism to reduce CV risk as a result of IR and chronic
inflammatory state in these patients.
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[21] M. A. González-Gay, M. T. Garćıa-Unzueta, C. González-
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